News | Heart Valve Technology | August 05, 2015

Abbott Expands Mitral Valve Therapy Offerings With Pair of Transactions

Technologies from Tendyne Holdings, Cephea Valve Technologies brought into Abbott fold

Abbott, purchase, Tendyne Holdings Inc., Cephea Valve Technologies, mitral valve therapies

August 5, 2015 — Abbott announced Monday that it has entered into an agreement to purchase Tendyne Holdings Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies. Under the terms of the agreement, Abbott will acquire the equity of Tendyne that it does not already own for $225 million upfront, resulting in a total transaction value of $250 million, plus potential future payments tied to regulatory milestones.

Tendyne's Bioprosthetic Mitral Valve System is an investigational device and not currently available for sale. The U.S. Food and Drug Administration has provided approval for a feasibility clinical trial to provide data about the device's safety and effectiveness. The trial has begun enrolling patients, and there are plans to begin enrollment next year in a clinical trial to support CE Mark in Europe.

In a separate transaction, Abbott has provided capital and secured an option to purchase Cephea Valve Technologies. Cephea Valve Technologies, a private company, is developing a catheter-based mitral valve replacement therapy. Financial terms were not disclosed.    

As part of its structural heart portfolio, Abbott currently offers MitraClip, a mitral valve repair device used to treat certain types of mitral valve disease, the most prevalent heart valve disease. It is delivered to the heart via a catheter through the femoral vein. MitraClip is available in the United States, Canada, Europe and countries in Asia and Latin America.

The Tendyne and Cephea valve replacement technologies are designed to be implanted in a beating heart, without the need for open heart surgery, similar to MitraClip, thereby offering a new treatment option. Minimally invasive mitral valve repair and replacement is expected to become a multi-billion dollar market over the next 10 years.

Completion of the Tendyne acquisition is subject to customary closing conditions, including antitrust clearance.  It is expected to close in the third quarter of this year. Neither the Tendyne acquisition nor the option to purchase Cephea is expected to impact Abbott's ongoing full-year 2015 earnings-per-share guidance.

Tendyne is headquartered in Roseville, Minnesota, and Cephea is headquartered in Santa Cruz, California.

For more information: www.abbottvascular.com


Related Content

News | Structural Heart

May 24, 2023 — Medtronic announced two-year results of their Harmony Transcatheter Pulmonary Valve (TPV) System, which ...

Home May 24, 2023
Home
News | Structural Heart

May 19, 2023 — Abbott announced late-breaking data that add to the body of clinical evidence supporting the benefits of ...

Home May 19, 2023
Home
News | Structural Heart

May 17, 2023 — Edwards Lifesciences announced that new data from the Benchmark Registry in Europe demonstrated the ...

Home May 17, 2023
Home
News | Structural Heart

March 16, 2023 — Cardiologists at the UW Medicine Heart Institute recently performed a first-in-the-world procedure ...

Home May 16, 2023
Home
News | Structural Heart

May 16, 2023 — Henry Ford Health Interventional cardiologists William O’Neill, M.D., and Khaldoon Alaswad, M.D., took a ...

Home May 16, 2023
Home
News | Structural Heart

May 15, 2023 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature ...

Home May 15, 2023
Home
News | Structural Heart

March 31, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's Epic Max ...

Home March 31, 2023
Home
News | Structural Heart

March 14, 2023 — The Society of Thoracic Surgeons (STS) has developed and launched a new risk calculator to estimate the ...

Home March 14, 2023
Home
News | Structural Heart

March 5, 2023 — In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure ...

Home March 05, 2023
Home
News | Structural Heart

March 4, 2023 — Abbott announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a ...

Home March 04, 2023
Home
Subscribe Now